Eterna Therapeutics (NASDAQ:ERNA) Stock Price Down 8.1% – What’s Next?

Eterna Therapeutics Inc. (NASDAQ:ERNA) shares were down 8.1% during trading on Tuesday . The company traded as low as $0.86 and last traded at $0.91. Approximately 105,356 shares changed hands during mid-day trading, an increase of 615% from the average daily volume of 14,735 shares. The stock had previously closed at $0.99.

Eterna Therapeutics Price Performance

The stock has a market cap of $4.92 million, a PE ratio of -0.21 and a beta of 4.39. The business has a fifty day moving average of $1.39 and a 200 day moving average of $1.75.

Eterna Therapeutics (NASDAQ:ERNA) last issued its quarterly earnings results on Tuesday, August 13th. The company reported ($1.02) EPS for the quarter. The business had revenue of $0.05 million during the quarter. Eterna Therapeutics had a negative net margin of 14,765.43% and a negative return on equity of 1,466.71%.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Eterna Therapeutics stock. Avidian Wealth Solutions LLC bought a new position in shares of Eterna Therapeutics Inc. (NASDAQ:ERNA) during the first quarter, according to the company in its most recent disclosure with the SEC. The firm bought 14,798 shares of the company’s stock, valued at approximately $36,000. Avidian Wealth Solutions LLC owned about 0.27% of Eterna Therapeutics as of its most recent SEC filing. 70.55% of the stock is owned by institutional investors and hedge funds.

Eterna Therapeutics Company Profile

Eterna Therapeutics Inc, a life science company, provides mRNA cell engineering technologies. Its technologies include mRNA cell reprogramming and gene editing; NoveSlice and UltraSlice gene-editing proteins; and the ToRNAdo mRNA delivery system. The company has a license agreement with Factor Bioscience Limited.